Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Shareholder Meeting (June 2020)
17 slides from Provectus Biopharmaceuticals's shareholder meeting presentation, Jun 24, 2020
Slide 1: 2020 Annual Shareholder Meeting
PROVECTUS BIOPHARMACEUTICALS, INC. 2020 Annual Shareholder Meeting Wednesday, June 24 10025 Investment Drive, Suite 250, Knoxville, Tennessee, USA 37932 © www.provectusbio.com
Slide 2: Forward-Looking Statements
PROWECTUS BIOPHARMACEUTICALS, INC. Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect Company management's current knowledge, assumptions, beliefs, estimates, and expectations, and express Provec
Slide 3: Today's Agenda
PROWECTUS BIOPHARMACEUTICALS, INC. Today's Agenda o Shareholder Meeting Activities o Company Update - Welcome/Introduction - Opening Remarks - Preliminary Matters - Developing a New Generation - Order of Business/Other Business of Immunotherapy Medicines - Inspector of the Election Report ~Q&A - Con
Slide 4: Part 1: Shareholder Meeting Activities
PROVECTUS BIOPHARMACEUTICALS, INC. Part 1: Shareholder Meeting Activities © 2020, Provectus Biopharmaceuticals, Inc. 4
Slide 5: Activities
PROWECTUS BIOPHARMACEUTICALS, INC. Activities o Welcome o Order of Business o Introductions - Proposal #1: To elect 5 directors to © Preliminary Matters serve on our Board of Directors for . a 1-year term - Inspector of the Election - Proposal #2: To conduct an - Record Date : advisory vote to appro
Slide 6: Part 2:
PROVECTUS BIOPHARMACEUTICALS, INC. Part 2: Company Update
Slide 7: Opening Remarks
PROVECTUS BIOPHARMACEUTICALS, INC. Opening Remarks Ed Pershing, CPA, Chair, Board of Directors © 2020, Provectus Biopharmaceuticals, Inc. ra
Slide 8: Developing a New Generation of Immunotherapy Medicines
PROVECTUS BIOPHARMACEUTICALS, INC. Developing a New Generation of Immunotherapy Medicines Dominic Rodrigues, Vice Chair, Board of Directors © 2020, Provectus Biopharmaceuticals, Inc. 8
Slide 9: Core Oncology Drug Development Strategy On-Track
PROWECTUS BIOPHARMACEUTICALS, INC. Core Oncology Drug Development Strategy On-Track © Continuing our pivot of intratumoral (IT) administration of immunotherapy PV-10 towards treatment-refractory and immunologically cold tumor types, such as hepatic cancers - Where immune checkpoint blockade (CB) and
Slide 10: A. Refractory/Relapsed Hepatic Cancers
PROWECTUS BIOPHARMACEUTICALS, INC. A. Refractory/Relapsed Hepatic Cancers ° Response, durability, and survival data of PV-10-based treatment in MUM, mNET, and HCC o mUM1!: Single-agent setting and in combination with unapproved but emerging standard of care CB; ongoing clinical work to identify T ce
Slide 11: B. Melanoma Has Not Been Cured
PROWECTUS BIOPHARMACEUTICALS, INC. B. Melanoma Has Not Been Cured © Continuing to advance Provectus’ historical work on combination immunotherapy of PV-10+PD-1 for cutaneous melanoma (MEL): - CB-naive Stage IV - CB-refractory Stage IV - In-transit (Stage Ill) disease (i.e., CB-naive); CB is approved
Slide 12: The Immunotherapy Platform
The Immunotherapy Platform PROWECTUS BIOPHARMACEUTICALS, INC. »»a> MODE OF DELIVERY HALOGENATED XANTHENES (HXS) Activity & MECHANISM 0 Concentration o Lead molecule: rose bengal 0 Modal; Selective © Exposure time Sout (RE) © Direct oiRoutetek © Multi-mode safety profile administration o Molecular tr
Slide 13: A. Drug Development Expansion: Hematology
PROWECTUS BIOPHARMACEUTICALS, INC. A. Drug Development Expansion: Hematology o Completed in vitro study on refractory/relapsed pediatric acute lymphoblastic leukemia (ALL)! © Completed in vitro study on refractory/relapsed pediatric acute myelomonocytic leukemia? - PV-10 treatment activated the STIN
Slide 14: B. Drug Development Expansion: Virology
PROWECTUS BIOPHARMACEUTICALS, INC. B. Drug Development Expansion: Virology © Third-party data demonstration of in vitro and in vivo RB activity against various groups of viruses: e.g., alphaherpesviruses (HSV-1)!, orthomyxoviruses (influenza A)23, paramyxoviruses (Sendai), poxviruses (vaccinia)*, rh
Slide 15: 2019-2020 Medical Conference Presentations
PROWECTUS BIOPHARMACEUTICALS, INC. 2019-2020 Medical Conference Presentations 1. APhase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium: Cohort 1 Results; August 2019, Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientif
Slide 16: Q&A
PROVECTUS BIOPHARMACEUTICALS, INC. Q&A Board of Directors © 2020, Provectus Biopharmaceuticals, Inc. 16
Slide 17: Closing Remarks
PROVECTUS BIOPHARMACEUTICALS, INC. Closing Remarks Bruce Horowitz, COO and Member, Board of Directors © 2020, Provectus Biopharmaceuticals, Inc. 17
Provectus Biopharmaceuticals — Shareholder Meeting (June 2020) on 6ix